Transgenomic, Key Genomics, CombiMatrix, National Union Fire Insurance Company, American International Group, Biocare, Invitrogen, New Zealand Research Science and Technology Ministry, New Zealand Genomics Limited, Bulgarian State Agency for Information T | GenomeWeb
Transgenomic, Key Genomics Teaming on Ovarian Cancer Treatment Test
 
Transgenomic said this week that it will work with Key Genomics to develop a molecular test to help physicians find out which ovarian cancer patients will respond to a certain drug treatment.
 
The test will couple Key Genomics’ coexpression extrapolation, or COXEN, predictive algorithm with Transgenomic’s DNA mutation detection analysis technology to predict epithelial carcinoma of the ovary.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.